Cara | $8,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
TippingPoint Biosciences
United States
- San Francisco, California
- 02/04/2026
- Seed
- $4,500,000
TippingPoint Biosciences is dedicated to creating new approaches to treat diseases of genome packaging such as hard-to-treat cancers and improve the quality of life of the patients.
Launched in 2023, TippingPoint Biosciences is an SF-based therapeutic company with a mission to improve and save the lives of patients who suffer from diseases with high unmet needs. Co-founded by Dr. Laura Hsieh, American Cancer Society Fellow and Dr. Geeta J. Narlikar, UCSF Professor of Biochemistry and Biophysics and National Academy of Sciences Member, TippingPoint Biosciences is a startup that was inspired by the ground-breaking discoveries made in Dr. Narlikar’s laboratory at UCSF. The company has built a new type of drug discovery platform to identify treatments for diseases caused by defects in DNA packaging, which include several hard-to-treat cancers. TippingPoint’s proprietary platform addresses major limitations and challenges seen in the healthcare space by recreating the biological context of cancer-driving chromatin states in a controlled, cell-free environment. Rather than targeting a single factor, TippingPoint’s platform focuses on disrupting or restoring the unique protein-protein and protein-DNA networks that package cell genomes. Unlike individual factors that may have similar functions in both healthy and diseased cells, the DNA packaging networks in cancer cells are significantly different, and can be exploited to enhance drug specificity and limit drug resistance.
As the only company that is directly targeting genome packaging states known to cause disease, TippingPoint is developing an entirely new class of drugs to treat disease.
To learn more, please visit https://tippingpointbiosciences.com/.
- Industry Biotechnology Research
- Website https://www.tippingpointbiosciences.com/
- LinkedIn https://www.linkedin.com/company/tippingpoint-biosciences/
Related People
Laura Hsieh, PhDFounder
United States -
San Francisco, California
As CEO & Founder of TippingPoint Biosciences, the first company to drug whole chromatin networks, I am deeply passionate about our mission to treat diseases caused by dysfunctional chromatin packaging. A scientist, researcher and entrepreneur, I am committed to improving and saving the lives of patients who suffer from diseases with unmet needs and utilizing my background to create industry-revolutionizing solutions that continue to innovate medicine.
At TippingPoint Biosciences, I lead the company’s vision and strategy, including identifying and developing tactics to reach our key milestones, and addressing critical areas for business growth. I have successfully raised a pre-seed round that enabled our transition out of UCSF into a MBC BioLabs incubator space in San Francisco. I am proud to have invented a proprietary, game-changing screening platform that is designed to make a difference in the lives of patients.
In 2019, I was awarded the prestigious American Cancer Society postdoctoral fellowship. During my time in academia, I have also led and published multiple peer-reviewed articles.
I received my Ph.D. in Molecular and Cellular Biology at the University of Washington/Fred Hutchinson Cancer Research Center and served as a postdoctoral researcher at UCSF in the lab of Dr. Geeta Narlikar. My 14-years of expertise is rooted in the expansive laboratory research and training that I received on specialized techniques including genomics and bioinformatics, genetics, molecular biology, cell biology, biochemistry, biophysics and structure-based docking.
During my undergraduate studies at Scripps College, where I majored in Molecular Biology, I realized my passion for research and the importance of contributing to the mechanistic understanding of biology and disease. My first research experience was in the lab of Dr. Jennifer Armstrong at the Claremont Colleges, where I fell in love with chromatin research and began my career in the field.
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Variance | $21,500,000 | (Apr 2, 2026)
Linx Security | $50,000,000 | (Apr 2, 2026)
Quantcore | $3,318,962 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)
Semarion | $3,800,000 | (Apr 2, 2026)
Via Separations | $36,000,000 | (Apr 2, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)